A nemia is common during hospital admission, particularly for patients in intensive care units (ICUs). In one prospective study, nearly 75% of patients admitted to the ICU either had or developed anemia. 1 Traditional first-line therapy for anemia during serious illness has been red blood cell (RBC) transfusion. As a result, RBCs are frequently administered to critically ill patients who are at risk for, are developing, or have serious infections. However, transfusion carries well-known acute and chronic risks, which increase with the number of RBC units administered and can result in organ injury and death. [2] [3] [4] [5] In one meta-analysis including 7456 hospitalized patients, randomization to a liberal compared to a restrictive RBC transfusion strategy was associated with an increased risk of serious infection. 5 Furthermore, recent evidence from human and animal studies suggests that transfusion of the oldest stored RBC units amplifies transfusion risks, particularly during infection. [6] [7] [8] [9] [10] To mitigate transfusion risks, alternative therapy with parenteral iron has been advocated for mild to moderate anemia. For many patients, parenteral iron provides an effective means of increasing RBC mass while decreasing transfusion requirements. [11] [12] [13] Recent reports have shown that the intravenous (IV) iron used off label in such settings as orthopedic surgery or postpartum hemorrhage or in patients receiving chemotherapy for gynecologic cancers is successful in reducing transfusions. [14] [15] [16] [17] [18] [19] IV iron has also been used to correct anemia where transfusion is not possible, such as in patients who decline transfusion on religious grounds. 20 These data have promoted the notion that many types of hospitalized patients with anemia or those at risk for blood loss may benefit from receiving IV iron and have increased its off-label use. Thus, current use of parenteral iron includes many types of hospitalized surgical patients as well as patients with anemia and many who are at risk for developing or have infections.
The current IV iron preparations are reportedly safer, easier to use, and better tolerated than the original IV iron dextran formulation. [21] [22] [23] However, parenteral iron therapy still has the potential to overwhelm normal iron-binding proteins, such as transferrin, releasing free iron into the circulation and potentially increasing bacterial infection risks. [24] [25] [26] Despite widespread use of IV iron therapy to minimize the need for RBC transfusion, the potential comparative risks have not been well established for these two therapies in anemic patients at risk for or with established infection.
In our validated canine model of bacterial pneumonia, transfusion of older RBCs (42 days old) increased hemolysis and release of cell-free hemoglobin (CFH) and free iron compared with transfusion of fresh (7-day-old) RBCs. This increase in free iron during infection was associated with increased lung injury and higher mortality. 27, 28 We hypothesized that if free iron is the mechanism of increased morbidity and mortality, treatment with transfused fresher RBCs, associated with limited hemolysis and minimal release of free iron, should prove superior to IV iron therapy in our model of severe bacterial infection and anemia. To test this, we randomly assigned infected animals with mild to moderate anemia to treatment with one of two iron preparations: either iron sucrose, one of the most commonly used preparations, or ferumoxytol, a newer iron formulation that may limit infection risk because it blunts free iron levels. We compared these two iron preparations to transfusion with fresh RBCs with minimal free iron release. The findings should help define the role and potential toxicities of IV iron treatment in blood management.
MATERIALS AND METHODS

Study design
Purpose-bred beagles (12-24 months old and weighing 9-12.5 kg) were randomly assigned to one of three treatments: 1) commercially available, canine universal-donor leukoreduced RBCs units (20 mL/kg, equivalent to transfusion of 2-4 units of human RBCs, n 5 18) stored for 7 days in CPDA-1 (DEA1.1, American Blood Resources International), 2) IV iron sucrose therapy (7 mg/kg, n 5 13), or 3) IV ferumoxytol therapy (7 mg/kg, n 5 11). The dosages and time of administration of the two iron preparations were derived from a weight-based weekly maximal dosing recommendation by the manufacturer of each formulation. In each iron preparation, the dosage is expressed as milligrams of elemental iron per milliliter. Ferumoxytol contains 30 mg of iron/mL and iron sucrose contains 20 mg/mL. Four animals were randomly assigned each week of the 96-hour study; one or two animals received transfused RBCs and one or two animals received one of the two iron preparations. During one study week, ferumoxytol was unavailable, so more iron sucrose animals were studied overall; but every week at least one transfused RBC animal and at least one animal receiving one of the two iron preparations were randomly assigned to be studied.
The primary endpoint was 96-hour mortality and secondary endpoints included the degree of shock, determined from the level of vasopressor support required to maintain mean pressure and lung injury, as measured by the alveolar-arterial oxygen gradient (AaO 2 gradient) over the course of the study. Although the marked differences in treatment arms precluded effective blinding, technicians caring for the animals over the 96 hours were not involved in designing the study or aware of the hypothesis tested and used set algorithms to guide care.
This model of Staphylococcus aureus pneumonia has been described previously. 29 Briefly, on Day 0 animals under general anesthesia were instrumented (femoral, external jugular, and urinary catheters), underwent tracheostomy, and received a balloon-tipped thermodilution pulmonary artery catheter through the external jugular catheter. The animals were then weaned from anesthesia, sedated with IV medications, and supported with mechanical ventilation (see Supplementary Methods, available as supporting information in the online version of this paper, for details). After achieving steady state, baseline echocardiogram, hemodynamic, and laboratory measures were obtained ( Fig. 1 ). At 0 hours S. aureus (0.5 3 10 9 -1.5 3 10 9 CFUs/kg) was administered into the right lower lobe of the lung. Two hours after bacterial inoculation, the animals underwent controlled hemorrhage removing 25% of total blood volume (20 mL/kg over 30 min) resulting in mild anemia. To maintain intravascular volume the removed blood was replaced with normal saline in a 2:1 ratio per milliliter of blood loss (40 mL/kg over 30 min). At 4 hours, the animals were randomly assigned to receive treatment with RBC transfusion (20 mL/kg transfused over 30 min), iron sucrose (IV over 6 hr, 1 mg/mL in normal saline), or ferumoxytol (IV over 1 hr, 1 mg/mL in normal saline). From 4 to 96 hours, all animals received standard ICU support titrated to standardized physiologic endpoints using algorithms designed to treat fully developed sepsis. 29 Laboratory measures including blood cultures, hemogram, metabolic panel, and iron quantification including free iron as measured by non-transferrin-bound iron (NTBI) levels, CFH levels, and transferrin-bound iron (TBI) levels were completed at the time points shown in Fig. 1 . Animals alive at 96 hours were considered survivors and were euthanized. The Animal Care and Use Committee at the National Institutes of Health approved this study before animals were enrolled.
Statistical analysis
Survival times were plotted using Kaplan-Meier survival curves and analyzed using log-rank tests. Survival is the primary endpoint. The analysis of all other endpoints are exploratory and the results are reported without accounting for multiple comparisons. For all other variables, changes from baseline values were analyzed in linear mixed models to account for the correlation of animals studied in each cycle and the repeated measures within each animal. Because the majority of animals died after the 48-hour time point, we only analyzed the first 48 hours for all endpoints except survival. All p values are twotailed and considered significant if p 0.05. For some variables, logarithm transformation was used when necessary.
Computer software (SAS Version 9.3, SAS Institute) was used for all analyses in this study. A power analysis was not conducted as this was a pilot study.
RESULTS
Survival
Animals randomly assigned to receive transfused stored fresh RBCs had a significantly lower mortality rate (n 5 18, 44%) compared to animals randomized to ferumoxytol therapy (n 5 11, 91%, p 5 0.04) or iron sucrose therapy (n 5 13, 92%, p 5 0.01; log rank test; Fig. 2 ).
Shock score and lung injury
Shock score
All animals were treated with vasopressors to normalize blood pressure. The shock score provides a relative index incorporating the amount of vasopressor (norepinephrine) required to normalize the mean arterial pressure. At 4 hours, just before treatment, there was no significant difference in the shock scores in all animals studied (p 5 0.22; Fig. 3A ). During the first 48 hours, animals transfused with fresh RBCs remained normotensive with mean shock scores similar to baseline. At 16 hours compared to the transfused fresh RBCs group, animals infused with ferumoxytol or iron sucrose developed significantly worse shock scores (p 5 0.003 and p 5 0.02, respectively). By 24 hours, the shock score continued to worsen (p 5 0.0007) in the iron sucrose group compared to those transfused fresh RBCs. By 48 hours the shock scores in both the ferumoxytol and iron sucrose animals and the animals transfused fresh RBCs no longer differed (p 5 0.72 and p 5 0.06, respectively).
Lung injury
Animals treated with ferumoxytol or with iron sucrose had greater increases in lung injury as measured by the mean AaO 2 at both 24 and 48 hours compared to animals transfused with fresh RBCs (p 5 0.007 and 0.001 for ferumoxytol and p 5 0.02 and 0.001 for iron sucrose, respectively; Fig. 3B ).
Pulmonary artery occlusion pressure, cardiac index, and hemoglobin levels
There were no significant differences comparing the iron groups and the transfused fresh RBCs group in mean cardiac filling pressures, measured by pulmonary artery occlusion pressure, or cardiac performance, measured by cardiac index or left ventricular ejection fraction (data not shown), throughout the study (all p > 0.07; Figs. 4A; and 4B). There were also no significant differences in mean hemoglobin (Hb) concentrations between treatment groups (all p 5 0.2-0.9; Fig. 4C ). In all groups throughout the study, mean Hb levels remained greater than 10 g/dL.
Mean values for Hb concentration were nominally higher in animals transfused fresh RBCs compared to those treated with either of the two iron preparations, but not significantly different.
Blood level measures of NTBI, TBI, and CFH NTBI At 4 hours, before iron or fresh RBC transfusion therapy, the mean plasma NTBI concentration was low and not significantly different among the three study groups (p 5 0.26; Fig. 5A ). After therapy with iron sucrose, compared to transfused fresh stored RBCs, marked significant increases in plasma mean NTBI levels were measured at all time points (7, 10, 13, 16, 24 , and 48 hr; p 5 0.04 to p < 0.0001). In contrast, compared to fresh RBC transfusion, animals treated with ferumoxytol had significant increases in plasma mean NTBI levels at only 7, 24, and 48 hours (p 5 0.04 to p 5 0.004).
TBI
Similar to NTBI, at 4 hours there was no significant difference in the plasma mean TBI levels at baseline between iron sucrose (74.2 6 6.6 mmol/L, mean 6 SE) and transfused fresh stored RBCs (75.9 6 8.2 mmol/L, p 5 0.82). From 7 to 48 hours the mean plasma levels of TBI in the iron sucrose group were significantly elevated (mean increase 28.5 6 12.0 mmol/L) compared to those receiving transfused fresh RBCs (p 5 0.02). Due to an interfering excipient in the diluent of ferumoxytol, TBI could not be quantified by electron paramagnetic resonance spectroscopy in this group.
CFH
There were no significant differences in plasma mean CFH throughout the study (Fig. 5B ) that could explain the significant increase in mortality, shock, or lung injury with the two iron therapies.
Other laboratory values
Measurements including those reflecting hepatic, renal, and metabolic function showed no significant differences throughout the study among the three groups (see Table  S1 , available as supporting information in the online version of this paper).
DISCUSSION
In a canine model of antibiotic-treated bacterial pneumonia with mild anemia, iron supplementation with either iron sucrose or ferumoxytol was associated with significantly worse outcomes compared to fresh blood transfusion. Animals treated with iron therapy developed more profound lung injury indicated by a greater increase in the AaO 2 gradient, more severe shock demonstrated by increased vasopressor requirements to maintain systemic pressure, and overall worse survival rates. We found marked increases in free iron levels in animals receiving both iron preparations for days after a single IV dose as used clinically to provide a weekly supply of iron; there were no significant increases in free iron levels after fresh blood transfusion. There were no significant differences in cardiac filling pressures or performance, Hb levels, or CFH levels to explain these findings. These data suggest that supplemental IV iron, but not transfusion of fresh blood, can raise plasma-free iron levels, thereby worsening the underlying bacterial infection and outcome.
Iron sucrose was studied because it is one of the most commonly utilized and relatively inexpensive parenteral iron formulations used to treat iron deficiency anemia. Preclinical and clinical studies document that administration is associated with elevations of plasma-free iron levels. [30] [31] [32] We found that iron sucrose, when administered at the maximum recommended weekly dose, overwhelmed ironbinding proteins and led to large increases in free iron at all time points measured during the first 48 hours after administration. Ferumoxytol was also studied because it blunts free iron levels in the circulation. This relatively newer iron oxide nanoparticle-based preparation reportedly has similar efficacy despite the blunting of free iron levels. The decreased free iron release into the circulation is due to direct reticuloendothelial uptake potentially limiting risks of IV iron administration during infection. [33] [34] [35] We found that administration of ferumoxytol at the maximum recommended weekly dose resulted in a brief peak of NTBI within 3 hours of infusion, which then normalized until a second increase occurred approximately 20 to 40 hours later. The differing free iron kinetics compared to iron sucrose with blunting of levels at approximately 3 to 20 hours after administration did not lead to any measurable clinically relevant decrease in toxicity. The second peak of free iron levels with ferumoxytol at 24 to 48 hours was unexpected and the mechanism remains uncertain. It is possible that with this preparation, iron is released from dysfunctional or apoptotic macrophages. The ability of iron to worsen infection ("the iron hypothesis") has been previously investigated. In murine models, with established infection either intraperitoneal Salmonella typhimurium 24 or S. aureus pyelonephritis, outcome was significantly worsened with iron therapy. 25 In other murine studies, the presence of circulating free iron decreased the colony numbers of bacteria necessary to cause death. 36, 37 In a study of human volunteers, transfusion with older RBCs resulted in measurable increases of circulating free iron and these patients' sera supported increased proliferation of Escherichia coli compared to sera from subjects receiving fresh RBCs with normal low levels of free iron. 38 A single oral dose of ferrous sulfate was shown in volunteers to increase transferrin saturation and total serum iron levels. Sera from these patients supported marked elevated growth and doubling time of four different bacterial species compared with serum collected before iron therapy. 39 Oral iron supplementation in children with anemia living in sub-Saharan Africa was associated with higher incidence of death related to infection. 40 Most prior clinical studies of iron did not directly compare RBC transfusion with IV iron infusion and limited comparisons to parenteral versus oral iron or different formulations of parenteral iron or placebo. A metaanalysis comparing parenteral to oral iron including 10,390 hospitalized patients found no increased risk, but another study, including 10,605 hospitalized patients, found a significantly increased risk of infection with IV iron administration. 41, 42 So it is possible that IV iron increases the risk of infection more than oral preparations.
In an investigation of whether iron administration reduces transfusions in anemic critically ill patients, 140 such patients were randomized to receive either parenteral iron or placebo at ICU admission. Infected patients were not enrolled in this study. There was no significant decrease in transfusion requirements, but Hb concentrations were higher in recipients of iron at ICU discharge. 43 This study, which includes antibiotic use, precludes direct evidence of increased bacterial growth in the study animals. In several prior experiments using this same canine pneumonia model with exchange transfusions, we did find an association between changes in free iron levels as measured by NTBI and worsened outcomes in presence of infection. Transfusion with older stored RBCs (42 days old) versus fresher (7 days old) stored RBCs units caused marked increases in plasma levels of free iron. With increasing concentrations of bacterial challenges these increases in plasma-free iron levels were shown to decrease over time more rapidly and profoundly with the older blood in a dosedependent fashion. In parallel, older blood produced greater increases in hemodynamic shock, lung injury, and mortality, 28 consistent with consumption and utilization of the free iron. In uninfected normal canine controls or uninfected canines with hemorrhagic shock, older blood still produced marked increases in plasma free iron compared to fresh blood, but without the more rapid iron clearance or increased morbidity and mortality. 27 In a study of infected canines, which altered the age (7, 14, 21, 28 , or 42 days) of exchange transfused RBCs, only 7-day-old RBCs produced no increase in free iron and that cohort was associated with the most favorable outcomes. 44 These data in total further support the hypothesis that increased morbidity and mortality with elevated free iron levels during infection are due to bacterial utilization and worsening infection. Moreover, iron sucrose and ferumoxytol increase NTBI, a readily accessible source of free iron for microorganisms. This was not true for fresh RBCs, which might explain the improved survival with transfusion. Interpretations of our findings are subject to limitations. When under metabolic stress or high oxygen demands, large stores of splenic RBCs can be recruited in canines increasing the circulating hematocrit or preventing a measurable loss of circulating RBCs. 45 However, there is no evidence that canine iron kinetics in this circumstance differ from those of human subjects. It is 28 due to the use of antibiotics in our model, we are unable to obtain direct, quantitative evidence of increased pulmonary or systemic infection correlating with morbidity or mortality.
In conclusion, in an experimental large animal model, treatment of anemia with supplemental IV iron significantly increased morbidity and mortality when compared to transfusion of fresh RBCs in a dose equivalent to 2 to 4 units of human RBCs. These results support the hypothesis that the toxicity from old stored RBCs in the setting of established infection is mediated by increased free iron. Furthermore, if these results can be extrapolated to the clinical setting, treatment of patients with anemia with IV iron should be undertaken with caution in the setting of established infection. 
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article at the publisher's website. Table S1 . Serial mean ( 6 SE) values for laboratory indices measured including hepatic, renal and metabolic function at 4h, 16h, 24h, and 48h in transfusion, ferumoxytol and iron sucrose treatment groups. For both ferumoxytol and iron sucrose there were no significant differences when compared to transfusion for any of the indices (p 5 NS).
